Market Overview

Bloomberg Highlighting Comments from ISI's Schoenebaum: Believes Onyx Pharma Could Have Aggregated Survival Data from Kyprolis Trial, Could Have Access to Data, Says Amgen Should Still Be Interested in Onyx

Share:

This headline-only article is meant to show you why a stock is moving, the most difficult aspect of stock trading. Every day we publish hundreds of headlines on any catalyst that could move the stocks you care about on Benzinga Pro, our flagship platform for fast, actionable information that promotes faster, smarter trading.

Benzinga Pro has an intuitively designed workspace that delivers powerful market insight, and is the solution of choice for thousands of professional and retail traders across the world.

Stop Googling for information and check out Benzinga Pro. You will never again be left in the dark on when a stock moves. You’ll have what you need to act in real time — before the crowd.

Start your FREE 14-day trial of Benzinga Pro today.

Latest Ratings for ONXX

DateFirmActionFromTo
Nov 2013Stifel NicolausTerminates
Aug 2013Maxim GroupDowngradesBuyHold
Aug 2013Summer StreetDowngradesBuyNeutral

View More Analyst Ratings for ONXX
View the Latest Analyst Ratings

Posted-In: Analyst Color News Rumors M&A Analyst Ratings

 

Related Articles (AMGN + ONXX)